KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Net Income towards Common Stockholders (2018 - 2025)

Historic Net Income towards Common Stockholders for Aurinia Pharmaceuticals (AUPH) over the last 10 years, with Q3 2025 value amounting to $31.6 million.

  • Aurinia Pharmaceuticals' Net Income towards Common Stockholders rose 12052.84% to $31.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.9 million, marking a year-over-year increase of 44339.07%. This contributed to the annual value of $5.7 million for FY2024, which is 10736.27% up from last year.
  • According to the latest figures from Q3 2025, Aurinia Pharmaceuticals' Net Income towards Common Stockholders is $31.6 million, which was up 12052.84% from $21.5 million recorded in Q2 2025.
  • Aurinia Pharmaceuticals' Net Income towards Common Stockholders' 5-year high stood at $31.6 million during Q3 2025, with a 5-year trough of -$50.4 million in Q1 2021.
  • Its 5-year average for Net Income towards Common Stockholders is -$15.0 million, with a median of -$13.4 million in 2023.
  • As far as peak fluctuations go, Aurinia Pharmaceuticals' Net Income towards Common Stockholders plummeted by 10633.75% in 2021, and later skyrocketed by 307300.88% in 2025.
  • Aurinia Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$33.3 million in 2021, then grew by 21.84% to -$26.0 million in 2022, then decreased by 3.34% to -$26.9 million in 2023, then surged by 105.47% to $1.5 million in 2024, then soared by 2041.96% to $31.6 million in 2025.
  • Its last three reported values are $31.6 million in Q3 2025, $21.5 million for Q2 2025, and $23.3 million during Q1 2025.